INSYS Therapeutics, Inc., along with its affiliates, filed a joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on September 17, 2019. As per the plan filed, the holders of Administrative expense claims, professional fee claims, priority tax claims and other priority claims will either be paid in cash or any other treatment as per the Bankruptcy code. Secured claims will be paid in full cash or reinstated or any other treatment. Holders of Trade and other unsecured claims shall receive it’s pro rata share of (i) 100% of all Category 1 Distributions (ii) 0.5% of all Category 2 Distributions; and (iii) 7% of any Preference and Indemnification Proceeds. Holders of Insurance related claims shall receive 68.5% of all category 2 distributions. Holders of Hospital and NAS Monitoring Claims shall receive 31% of all category 2 distributions. Holders of DOJ claims shall receive 31.4 % of all category 3 distributions. Holders of SMT Group claims shall receive (i) 68.6% of all category 3 distributions. (ii) 5% of any product liability insurance proceeds and (iii) 100% of interest in any Excess Products Liability Insurance Proceeds. Holders of personal injury claims shall receive 95% of any Products Liability Insurance Proceeds. 510(a), 510(b), 510(c) subordinated claims and intercompany claims shall be deemed expunged, discharged, released, and extinguished without further action by or order of the Bankruptcy Court. Equity interests shall be deemed surrendered or cancelled. The plan will be funded through cash in hand and assets sales. The Liquidating Trustee will be selected by the mutual agreement of the Creditors’ Committee and the SMT Group Representatives prior to the Confirmation Hearing for distribution of claims.